{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-078719","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2023-07-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.999596+00:00","generated_at":"2026-06-13T12:14:52.157977+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Structure Therapeutics enters three facility leases in Shanghai and South San Francisco","bullets":["Operations lease for ~22,500 sq ft in Shanghai; annual rent ~5.20M yuan (~$0.72M); term Jan 2024–Dec 2026.","Lab lease for ~8,400 sq ft in Shanghai; annual rent ~1.99M–2.12M yuan (~$0.27–0.29M); term Feb 2024–Jan 2027.","Sublease for ~11,800 sq ft in South San Francisco; annual rent ~$0.49M initial +3% annual; term Aug 2023–Aug 2027, with 4-month rent abatement.","Leases support R&D operations in China and corporate headquarters in the US."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-078719","json":"https://secwatch.observer/filing/0001104659-23-078719.json","markdown":"https://secwatch.observer/filing/0001104659-23-078719.md","text":"https://secwatch.observer/filing/0001104659-23-078719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923078719/0001104659-23-078719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923078719/tm2319105d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T12:14:52.157977+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"245d9177e7e1f368056e220cfd83fb8053f982d5","claim":"Structure Therapeutics Inc. entered into Sublease with Aligos Therapeutics, Inc. valued at approximately US$0.49 million (effective 2023-06-29).","evidence_excerpt":"On June 29, 2023, Structure Therapeutics USA Inc., the Company’s wholly owned subsidiary (“Structure USA”) entered into a sublease agreement (the “Sublease”) with Aligos Therapeutics, Inc.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923078719/0001104659-23-078719-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"lease"},{"label":"Counterparty","value":"Aligos Therapeutics, Inc."},{"label":"Value","value":"approximately US$0.49 million"},{"label":"Effective","value":"2023-06-29"}],"fact_type":"material_agreement"},{"claim_id":"475ed101e701414050c2564aabb7d719613bd86a","claim":"Structure Therapeutics Inc. entered into Lab Lease with Shanghai Chuangzhi Space Entrepreneurship Incubator Management Co., Ltd. valued at approximately 1.99 million yuan, or approximately US$0.27 million (effective 2023-06-29).","evidence_excerpt":"On June 29, 2023, Shanghai ShouTi, entered into a lease agreement (the “Lab Lease”) with Shanghai Chuangzhi Space Entrepreneurship Incubator Management Co., Ltd.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923078719/0001104659-23-078719-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"lease"},{"label":"Counterparty","value":"Shanghai Chuangzhi Space Entrepreneurship Incubator Management Co., Ltd."},{"label":"Value","value":"approximately 1.99 million yuan, or approximately US$0.27 million"},{"label":"Effective","value":"2023-06-29"}],"fact_type":"material_agreement"},{"claim_id":"cf9cbbe2fdbaa23a9c7f1b450bfd3c2bc7f631f8","claim":"Structure Therapeutics Inc. entered into Operations Lease with Shanghai Changtai Business Management Co., Ltd. valued at approximately 5.20 million yuan, or approximately US$0.72 million (effective 2023-06-29).","evidence_excerpt":"On June 29, 2023, Shanghai ShouTi Biotechnology Co., Ltd., the Company’s wholly owned subsidiary. (“Shanghai ShouTi”) entered into a lease agreement (the “Operations Lease”) with Shanghai Changtai Business Management Co., Ltd.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923078719/0001104659-23-078719-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"lease"},{"label":"Counterparty","value":"Shanghai Changtai Business Management Co., Ltd."},{"label":"Value","value":"approximately 5.20 million yuan, or approximately US$0.72 million"},{"label":"Effective","value":"2023-06-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}